The first half of the year is over, and it may surprise some investors that European stocks are near

Novartis (NVS) is sitting at the center of a fast-growing oncology market as radioligand therapy gai

Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-

Antares Therapeutics, Inc. ("Antares"), a biotechnology company developing first-in-class pr

Europe has eased deportation rules of illegal migrants in response to rising public frustration over

Curium™ is pleased to announce that it has prevailed in the patent dispute brought by Novartis subsi

Novartis reports positive Phase 1/2 del-brax data in FSHD, supporting Phase 3 development of a poten

Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endp

Relay Therapeutics reported early Phase 2 data showing lesion reduction and symptom improvement with

Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges t

https://www.novartis.com/news/media-releases/new-psmaddition-data-show-58-lower-risk-psa-progression

The US Supreme Court turned away appeals from six pharmaceutical companies seeking to topple the Med

White House estimates Trump's drug pricing agreements could save $529 billion in next decade, bu

Sen. Warren challenges Trump's 600% TrumpRx drug price claim using a glass of water.

PTC Therapeutics stock drops after PIVOT-HD update, as FDA approval doubts offset dose-based benefit

Novartis CEO Vas Narasimhan warned that the Trump administration's "most favored nation"

Novartis (NYSE:NVS) reported quarterly earnings of $1.99 per share which missed the analyst consensu

Novartis announced today that the European Commission (EC) approved Rhapsido® (remibrutinib) for chr

Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europ

Merck cuts Terns deal price after TERN-701 data review, while maintaining interest amid competition

https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/october-december-2025-new-safety-

Merck to buy Terns for $6.7 billion as Keytruda patent risk nears, boosting leukemia pipeline; analy

Merck is reportedly nearing a $6 billion acquisition of Terns Pharmaceuticals to strengthen its onco

In November 2025, Olema Pharmaceuticals surged over 200% after Roche released phase 3 results from a

Novartis reached a confidential settlement with Henrietta Lacks' family, resolving a second laws

Novartis' RemIND trial shows oral remibrutinib offers breakthrough relief for chronic urticaria

International ETFs are gaining momentum as global markets outperform US stocks. Here's what'

The complete list of Super Bowl 2026 commercials from Super Bowl LX and the companies behind the ads

Avalo Therapeutics completed Phase 2 enrollment for AVTX-009, with mid-2026 data ahead. Cantor sees

CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding t

The FDA granted breakthrough status to Cogent's GIST drug combo after a trial showed it cut dise

Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of

Monte Rosa revealed positive interim Phase 1 data of MRT-8102. Data showed safety, tolerability, and

HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a

Accenture to acquire UK-based AI firm Faculty, adding 400 specialists and decision intelligence capa

Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfr

Healthcare ETFs stay resilient as Big Pharma agrees to Medicaid drug price cuts. Here's what is

Novartis raises long-term sales targets, boosts outlook for key medicines and outlines a pipeline st

President Donald Trump announced a framework for a trade deal with Switzerland and Liechtenstein on

Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth

U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest

Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright dow

Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12

Editor’s note: The future prices of benchmark tracking ETFs, and the headline were updated in the st